BioNTech, the company who developed the COVID-19 mRNA vaccine, is collaborating with the UK government to develop personalised mRNA immunotherapies for cancer and infectious diseases other than COVID-19. The collaboration will focus on providing up to 10,000 patients with personalised mRNA by 2030.
The partnership aims to carry out clinical trials in the UK, with a view to enrolling the first cancer patient this year. BioNTech are investing in a UK research and development hub in Cambridge, with more than 70 scientists later this year. A new headquarters will also be set up in London to sponsor clinical trials.